News Releases

Month Year

Month Year

Investor Alerts

Sep 19, 2022

IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Sep 14, 2022

IDEAYA Announces Pricing of Public Offering of Common Stock
Sep 14, 2022

IDEAYA Announces Proposed Public Offering of Common Stock
Sep 11, 2022

IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
Sep 6, 2022

IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma
Aug 30, 2022

IDEAYA Biosciences to Participate in Investor Conferences in September 2022
Aug 29, 2022

IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate
Aug 15, 2022

IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Jul 27, 2022

IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation
Jul 27, 2022

IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors

Show per page